Lipocine Inc at Ladenburg Thalmann Healthcare Conference Transcript
My pleasure to introduce our next presenting company, Lipocine. And presenting for the company is CEO, Mahesh Patel. Thanks.
All right. Thanks, Matt. Good afternoon, all, and thanks for participating. I am Mahesh Patel; I'm the President, CEO and Co-Founder of Lipocine.
First, 2022 has been a transformative year for Lipocine because we got our first product approved commercialized through a partner. And that means we have validated our technology, which I'll dive into more in detail. And we are truly excited about the opportunities that we're pursuing, and the future looks bright.
As you may know, a couple of days ago, we announced our strategy realignment with regards to our development focus targeted towards treating CNS disorders. And I'll tell you why, and also about our technology that is enabling us to engage in this forward focus on the CNS assets.
So before we do that, let's go through some official business, forward-looking statements. Give it a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |